Curonz is a clinical stage Neurotherapeutics company with the vision to transform the Quality of Life of severely neurologically affected children and adult patients.
Our approach involves a body and mind boosting drug therapy with a modified naturally occurring molecule named NRP2945 that controls seizure activity with simultaneous comorbidities improvement profiles in young patients diagnosed with epileptic encephalopathy syndromes like Lennox-Gastaut Syndrome and adults with drug resistant Temporal Lobe Epilepsy. NRP2945 exerts its activity via agonism of a novel CXCR4 receptor complex in an ultra-potent manner with no off-target effects.
Another strong benefit derives from the minimal adverse event profile displayed by our peptide drug NRP2945. Subcutaneous injections of fully formulated NRP2945 administered every-other-day provide for a well-tolerated administration scheme.
The NRP Discovery
A phenotypic brain tissue screen to monitor neuronal migration was used to initally screen compounds for their potential to generate neural outgrowth.
read moreClinical Trials
Curonz has completed a successful Phase I safety trial in healthy volunteers. We recently completed a small Phase II trial in patients with Absence Epilepsy.
read moreLennox Gastaut Syndrome
Lennox-Gastaut Syndrome is a refractory childhood epilepsy which falls under the disease category ultra-orphan drug destination. This is a epileptic encephalopathy.
read more